Chad
Tuberculosis profile
| High HIV burden |
Population  2013 13 million
Estimates of TB burden * 2013 Number (thousands) Rate
(per 100 000 population)
Mortality (excludes HIV+TB) 2.9 (1.6–3.8) 22 (13–29)
Mortality (HIV+TB only) 1.5 (0.94–2.3) 12 (7.3–18)
Prevalence  (includes HIV+TB) 26 (14–41) 200 (108–321)
Incidence  (includes HIV+TB) 19 (17–22) 151 (134–169)
Incidence (HIV+TB only) 4.6 (2.9–6.6) 36 (23–51)
Case detection, all forms (%) 58 (52–66)    
Estimates of MDR-TB burden * 2013   New   Retreatment
% of TB cases with MDR-TB 1.9 (0.1–5.3) 20 (0.1–40)
MDR-TB cases among notified pulmonary
TB cases
180 (10–500) 160 (1–330)
TB case notifications 2013 New ** Relapse
Pulmonary, bacteriologically confirmed 4 758   549
Pulmonary, clinically diagnosed 4 718   0
Extrapulmonary 1 212   0
       
Total new and relapse 11 237    
Previously treated, excluding relapses 268    
Total cases notified 11 505    
Among 11 237 new and relapse cases:
867 (8%) cases aged under 15 years; male:female ratio: 1.7
Reported cases of RR-/MDR-TB 2013 New Retreatment Total **
Cases tested for RR-/MDR-TB 2 (<1%)   2
Laboratory-confirmed RR-/MDR-TB cases     2
Patients started on MDR-TB treatment     0
TB/HIV 2013 Number (%)
TB patients with known HIV status 4 638 (40)
HIV-positive TB patients 1 073 (23)
HIV-positive TB patients on co-trimoxazole preventive therapy (CPT)    
HIV-positive TB patients on antiretroviral therapy (ART)    
HIV-positive people screened for TB    
HIV-positive people provided with IPT    
Treatment success rate (%)
New cases registered in 2012 69
Previously treated cases registered in 2012 56
HIV-positive TB cases, all types, registered in 2012  
RR-/MDR-TB cases started on second-line treatment in 2011  
XDR-TB cases started on second-line treatment in 2011  
Laboratories 2013  
Smear (per 100 000 population) 0.6
Culture (per 5 million population) 0
Drug susceptibility testing (per 5 million population) 0
Sites performing Xpert MTB/RIF 2
Is second-line drug susceptibility testing available? No
Financing TB control 2014  
National TB programme budget (US$ millions) 0
% Funded domestically  
% Funded internationally  
% Unfunded  
* Ranges represent uncertainty intervals
** Includes cases with unknown previous TB treatment history
***
(Rate per 100 000 population per year)
Mortality graph
   Mortality  (excludes HIV+TB)

(Rate per 100 000 population)
Prevalence graph
   Prevalence

(Rate per 100 000 population per year)
Incidence graph
   Notified (new and relapse)   Incidence
   Incidence (HIV+TB only)

(Number of patients)
CPT ART graph
   HIV-positive TB patients
   on CPT   on ART

Treatment success rate (%)
tx success graph
   New   Retreatment
   HIV-positive   RR-/MDR-TB   XDR-TB

Total budget (US$ millions)
Budget funding Graph
__Funded domestically__Funded internationally
__Unfunded
 
 Data are as reported to WHO. Estimates of TB and MDR-TB burden are produced by WHO in consultation with countries.
 Generated: 2015-07-07 Data: www.who.int/tb/data